Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) Jumps Ahead of Presentation to Investors
After a serious streak of days in the red, Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) is gaining in the past days, adding 9% on Tuesday to reach $0.0579. Dollar volumes were near $250,000, and on Wednesday, the ticker started up on opening. 
Like many other pharmaceutical stocks, AMBS is always boosted by positive news- in this case, a promising test result of Lympro, a blood test for Alzheimer’s disease that is still in the trials stage. The positive research data bring the test a step closer to market, where it would be a one of a kind diagnostic tool. Despite the promise, AMBS is still hovering below the 10-cent levels, and for a few months now has been reeling from the unsustainable price achieved during the summer promotions.
But here comes another boost, an investors’ conference, the other pathway to kindle interest in a biotech stock. AMBS will present at 6th annual Livingston Securities Life Science Stakeholders Summit on Thursday, October 17th – and we may expect this would support the price levels.
A lot of attention heaped on a stock is not always a good thing. An investors’ conference drew attention to International Stem Cell Corp. (OTCMKTS:ISCO), jumped temporarily to the peak of the range at 22 cents, but went on to slide to 17 cents immediately after.
Advanced Cell Technology, Inc. (OTCBB:ACTC) has more farfetched claims, though it hovers in a similar range to AMBS. The ticker has been stuck again, at around 6 cents in the past few days.
As for AMBS, dollar volumes remain cautious, revealing that this ticker has lost the enthusiastic support riled up by paid promoters. Volumes are erratic, despite the very regular press releases- but some of the news hardly generate attention. Still, the company is burdened by much debt, about $5.5 million, and has no revenues, only accumulating above $15 million losses. The company also has about 460 million shares outstanding, a weighty amount that may drag the shares down.
Several big names in the pharmaceutical sector are getting more active as presentations and conferences draw attention. Titan Pharmaceuticals, Inc. (OTCBB:TTNP) is still struggling to close the gap. So is OncoSec Medical, Inc. (OTCMKTS:ONCS), which recently lost a third of its price on choppy trading.
If you want exposure to the sector, keep in mind that tickers offer differing qualities, and AMBS is among the more speculative bids, relying on future promises to boost the positions. Stay away unless you can afford the fallout.
